Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ANNX NASDAQ:PHAT NASDAQ:SLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.38-2.0%$4.53$3.19▼$5.38$865.22M0.622.56 million shs876,393 shsANNXAnnexon$5.22-1.5%$5.36$2.03▼$7.18$855.26M1.164.98 million shs2.73 million shsPHATPhathom Pharmaceuticals$11.44-1.4%$10.86$8.02▼$18.31$912.41M0.491.14 million shs936,449 shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/AThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-3.95%-0.68%+4.29%+35.60%ANNXAnnexon0.00%-10.00%+1.36%-11.22%+110.48%PHATPhathom Pharmaceuticals0.00%+4.57%+10.64%-2.22%+33.49%SLRNAcelyrin0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.38-2.0%$4.53$3.19▼$5.38$865.22M0.622.56 million shs876,393 shsANNXAnnexon$5.22-1.5%$5.36$2.03▼$7.18$855.26M1.164.98 million shs2.73 million shsPHATPhathom Pharmaceuticals$11.44-1.4%$10.86$8.02▼$18.31$912.41M0.491.14 million shs936,449 shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/AThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-3.95%-0.68%+4.29%+35.60%ANNXAnnexon0.00%-10.00%+1.36%-11.22%+110.48%PHATPhathom Pharmaceuticals0.00%+4.57%+10.64%-2.22%+33.49%SLRNAcelyrin0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.0014.16% UpsideANNXAnnexon 2.20Hold$15.33193.74% UpsidePHATPhathom Pharmaceuticals 2.86Moderate Buy$24.50114.16% UpsideSLRNAcelyrin 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLRN, PHAT, ABUS, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ANNXAnnexon CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Underperform7/21/2026ANNXAnnexon Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Underperform$3.007/20/2026ANNXAnnexon HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.007/17/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026ANNXAnnexon Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $25.007/13/2026ANNXAnnexon Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/17/2026PHATPhathom Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$14.08M61.45N/AN/A$0.40 per share10.95ANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/APHATPhathom Pharmaceuticals$175.11M5.21N/AN/A($6.14) per share-1.86SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.28N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)ANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.33N/A-76.77%N/A-44.29%7/30/2026 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/ALatest SLRN, PHAT, ABUS, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ANNXAnnexon-$0.23N/AN/AN/A$6.50 millionN/A8/5/2026Q2 2026ABUSArbutus Biopharma-$0.02N/AN/AN/A$0.70 millionN/A7/30/2026Q2 2026PHATPhathom Pharmaceuticals-$0.06N/AN/AN/A$72.70 millionN/A5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AANNXAnnexonN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26ANNXAnnexonN/A6.356.35PHATPhathom PharmaceuticalsN/A2.212.16SLRNAcelyrinN/A7.157.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ANNXAnnexonN/APHATPhathom Pharmaceuticals99.01%SLRNAcelyrin87.31%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%ANNXAnnexon10.31%PHATPhathom Pharmaceuticals9.33%SLRNAcelyrin13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableANNXAnnexon60163.84 million146.95 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableSLRNAcelyrin135100.95 million86.68 millionNo DataSLRN, PHAT, ABUS, and ANNX HeadlinesRecent News About These CompaniesACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesMay 13, 2025 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with AlumisMay 6, 2025 | globenewswire.comAcelyrin urges stockholders to vote for proposed merger with AlumisMay 2, 2025 | finance.yahoo.comACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisMay 1, 2025 | globenewswire.comAlumis and ACELYRIN Announce Amended Merger AgreementApril 21, 2025 | globenewswire.comACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRNApril 16, 2025 | businesswire.comAlumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deAlumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30, 2025 | morningstar.comMInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockMarch 20, 2025 | insidertrades.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | finanznachrichten.deAcelyrin says Concentra indication not expected to result in superior proposalMarch 4, 2025 | markets.businessinsider.comAcelyrin falls as Acelyrin reaffirms deal commitmentMarch 4, 2025 | msn.comAcelyrin, Alumis reaffirm strategic, financial rationale of proposed mergerMarch 4, 2025 | markets.businessinsider.comACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRN, PHAT, ABUS, and ANNX Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.38 -0.09 (-2.01%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.38 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Annexon NASDAQ:ANNX$5.22 -0.08 (-1.51%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.22 0.00 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Phathom Pharmaceuticals NASDAQ:PHAT$11.44 -0.16 (-1.38%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.13 -0.31 (-2.71%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
